PMD Device Solutions AB Share Price

Equities

PMDS

SE0021513645

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 08:59:52 03/05/2024 pm IST 5-day change 1st Jan Change
7.3 SEK +1.39% Intraday chart for PMD Device Solutions AB -3.31% -35.34%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 49M 4.53M 377M Sales 2025 * 77M 7.11M 593M Capitalization 152M 14.06M 1.17B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 3.04 x
Net cash position 2024 * 3M 277K 23.11M Net cash position 2025 * 119M 11M 917M EV / Sales 2025 * 0.43 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 23.61%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on PMD Device Solutions AB

1 day+1.39%
1 week-3.31%
Current month-7.01%
1 month-27.00%
3 months-71.92%
More quotes
1 week
6.20
Extreme 6.2
8.70
1 month
6.20
Extreme 6.2
10.90
Current year
6.20
Extreme 6.2
112.64
1 year
6.20
Extreme 6.2
112.64
3 years
6.20
Extreme 6.2
112.64
5 years
6.20
Extreme 6.2
112.64
10 years
6.20
Extreme 6.2
112.64
More quotes
Date Price Change Volume
03/24/03 7.3 +1.39% 15,554
02/24/02 7.2 -8.28% 28,812
30/24/30 7.85 +9.79% 6,242
29/24/29 7.15 -5.30% 16,310

Delayed Quote Nasdaq Stockholm, May 03, 2024 at 08:59 pm IST

More quotes
PMD Device Solutions AB is a Sweden-based biopharmaceutical company. The Company deals with research, development and production of medical technical products and equipment and related activities. It specializes in the development of therapeutic peptides for the bioactive wound care market. The Company possesses two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase. The peptides are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 aims to prevent post-surgical adhesions and scars and is for clinical phase III-studies on patients performing tendon repair surgery in the hand. LL-37 aims to heal chronic wounds and is in a clinical phase IIb study on patients with venous leg ulcers and in a clinical phase IIa study on patients with diabetic foot ulcers. PMD Device Solutions AB develops and sells medical products for respiratory monitoring.
Calendar
More about the company

Chiffre d''affaires - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW